Strategies in API Scale Up - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Strategies in API Scale Up
Process chemists employ a variety of approaches to improve yield, purity, and stereoselectivity.


Pharmaceutical Technology
Volume 37, Issue 1, pp. 52-54

Aromatic nitration reactions

Biocatalysis can play an important role in synthetic chemistry by providing more efficient chemical transformations and improving process conditions. Such is the case for chemists at the University of Warwick in the United Kingdom, who in collaboration with researchers at Cornell University in New York, recently reported on the discovery of an enzyme in the bacterium Streptomyces scabies that catalyzes an aromatic nitration reaction (6).


Drug development focus: orphan drugs
The researchers assert that TxtE, a cytochrome P450 enzyme, is the first example of an enzyme that has specifically evolved to catalyze an aromatic nitration reaction, according to a Sept. 21, 2012, University of Warwick, press release. It does this by using the gases nitrogen monoxide, generated from the amino acid arginine by the nitric oxide synthase partner enzyme txtD, and dioxygen. Engineering of the TxtE enzyme may allow it to be developed as a nitration biocatalyst for the production of industrial chemicals without the need to use nitric acid.

Cytochrome P450 enzymes are widespread in living organisms. Usually, they are responsible for hydroxylation and other oxidative reactions, but this is the first time that they have been reported to catalyze a nitration reaction, according to the researchers. TxtE catalyzes the introduction of a nitro group into a specific position of the aromatic ring of the amino acid tryptophan. This is the first key step in the biosynthesis of thaxtomin A.

Patricia Van Arnum is a executive editor of Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ 08830
tel. 732.346.3072,
. twitter@PharmTechVArnum

References

1. "Catalyst: Putting Cyanide to Work", A*Star Research, online, http://www.research.a-star.edu.sg/research/6566/, Oct. 10, 2012.

2. A.M. Seayad et al., Chemistry–A European Journal 18 (18), 5693–5700 (2012).

3. I. Marek et al, Nature 490 (7421), 522–526 (2012).

4. B.E. and N. Cramer, Science 338 (6106), 504–506 (2012).

5. C. Zhu and S.P. Cook. J. Am. Chem. Soc. 134 (33), 13577–13579 (2012).

6. G. Challis, Nature Chem. Biol. 8 (10), 814–816 (2012).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here